Evidence map›Paper›PMID 34852704›Full record

ArticleTherapeutic advances in respiratory disease

Inhibition of LC3-associated phagocytosis in COPD and in response to cigarette smoke.

Patrick F Asare, Hai B Tran, Plinio R Hurtado, Griffith B Perkins, Phan Nguyen, Hubertus Jersmann, Eugene Roscioli, Sandra Hodge

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. When clearance fails: the role of efferocytosis in COPD.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Efferocytosis in Homeostasis.Advances in experimental medicine and biology · 2025
    Review
  9. Review
  10. Metabolic Implications of Efferocytosis During Inflammation.Advances in experimental medicine and biology · 2025
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Efferocytosis and Respiratory Disease.International journal of molecular sciences · 2023
    Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Patrick F AsareDepartment of Thoracic Medicine, School of Medicine, The University of Adelaide, Adelaide, SA, Australia.ORCID 0000-0001-6389-4978
Hai B TranDepartment of Thoracic Medicine, School of Medicine, The University of Adelaide, Adelaide, SA, Australia.
Plinio R HurtadoDepartment of Renal Medicine, School of Medicine, The University of Adelaide, Adelaide, SA, Australia.
Griffith B PerkinsDepartment of Molecular and Cellular Biology, School of Biological Sciences, The University of Adelaide, Adelaide, SA, Australia.
Phan NguyenDepartment of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia.
Hubertus JersmannDepartment of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia.
Eugene RoscioliDepartment of Thoracic Medicine, School of Medicine, The University of Adelaide, Adelaide, SA, Australia.
Sandra HodgeDepartment of Thoracic Medicine, Faculty of Health and Medical Science, The University of Adelaide, Adelaide, SA 5005, Australia.
Royal Adelaide Hospital · AUThe University of Adelaide · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction/rationaleIn chronic obstructive pulmonary disease (COPD), defective macrophage phagocytic clearance of cells undergoing apoptosis by efferocytosis may lead to secondary necrosis of the uncleared cells and contribute to airway inflammation. The precise mechanisms for this phenomenon remain unknown. LC3-associated phagocytosis (LAP) is indispensable for effective efferocytosis. We hypothesized that cigarette smoke inhibits the regulators of LAP pathway, potentially contributing to the chronic airways inflammation associated with COPD.

methodsBronchoalveolar (BAL)-derived alveolar macrophages, lung tissue macrophages obtained from lung resection surgery, and monocyte-derived macrophages (MDM) were prepared from COPD patients and control participants. Lung/airway samples from mice chronically exposed to cigarette smoke were also investigated. Differentiated THP-1 cells were exposed to cigarette smoke extract (CSE). The LAP pathway including Rubicon, as an essential regulator of LAP, efferocytosis and inflammation was examined using western blot, ELISA, flow cytometry, and/or immunofluorescence.

resultsRubicon was significantly depleted in COPD alveolar macrophages compared with non-COPD control macrophages. Rubicon protein in alveolar macrophages of cigarette smoke-exposed mice and cigarette smoke-exposed MDM and THP-1 was decreased with a concomitant impairment of efferocytosis. We also noted increased expression of LC3 which is critical for LAP pathway in COPD and THP-1 macrophages. Furthermore, THP-1 macrophages exposed to cigarette smoke extract exhibited higher levels of other key components of LAP pathway including Atg5 and TIM-4. There was a strong positive correlation between Rubicon protein expression and efferocytosis.

conclusionLAP is a requisite for effective efferocytosis and an appropriate inflammatory response, which is impaired by Rubicon deficiency. Our findings suggest dysregulated LAP due to reduced Rubicon as a result of CSE exposure. This phenomenon could lead to a failure of macrophages to effectively process phagosomes containing apoptotic cells during efferocytosis. Restoring Rubicon protein expression has unrecognized therapeutic potential in the context of disease-related modifications caused by exposure to cigarette smoke.

Indexed as

PhagocytosisPulmonary Disease, Chronic ObstructiveAnimalsHumansLungMacrophages, AlveolarMiceSmokingcigarette smoke extractefferocytosisinflammationLC3-associated phagocytosisRubicon

Identifiers

PMID34852704
PMCPMC8647217
OpenAlexW3215493275

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.